Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

MongoDB

Trade Desk

These stocks might have seemingly lofty valuations, but their tremendous prospects make them worth every penny.

3 Hot Growth Stocks I'd Buy Right Now

Harnessing the power of tumor profiling from a liquid biopsy, Guardant Health is delivering hopes to investors while rewarding shareholders with robust gains.

Guardant Health: Profiting From Precision Medicine

Vertex Pharmaceuticals

Great businesses plus great growth opportunities could add up to 100% or more returns for these stocks.

3 Stocks That Could Double Your Money: GH, TTD & VRTX

Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital.

What Should Investors Make of Guardant Health's Newest Competitor?

Beyond Meat

HUYA Inc - ADR

Investors aiming to buy into the next big thing may want to take a look. But beware: Sometimes the market already expects great things.

Three High-Growth Stocks That Are Just Getting Started

It's a leader in an early-stage area with massive growth potential.

Here's My 'Top Stock' to Buy in June

bluebird bio

Bristol-Myers

Exelixis

Illumina

These stocks are leading the way in their respective areas in battling cancer.

Top 5 Stocks in the Fight Against Cancer

The liquid biopsy pioneer announced strong operating results from the first three months of the year.

Here's Why Guardant Health Jumped 17.4% in May

Advanced Micro Devices

Coupa Software

General Motors

Morgan Stanley

AMD stock, General Motors, Coupa earnings, Morgan Stanley and Guarant Health are our top stock trades for Wednesday.

5 Top Stock Trades for Wednesday: AMD, COUP, GM, MS & GH

Avalara Inc

Iovance Biotherapeutics

Mirati Therapeutics

Spark Therapeutics

Roku

Sinclair Inc

Snap

Pfizer

Roku, Array Biopharma and Guardant Health are just some of the best stocks by returns for the first half of 2019. The post The 10 Best Stocks for 2019 — So Far appeared first on InvestorPlace.

The 10 Best Stocks for 2019 — So Far

Novocure

Veeva Systems

These top healthcare stocks could be worth adding to portfolios if the market sells off sharply.

3 Fast-Growing Healthcare Stocks to Buy If the Market Crashes

CannTrust Holdings

Redfin

If you're looking to level up, these stocks could be just what you need.

Three Small-Cap Stocks, With Big-Cap Potential.

Arrowhead Pharmaceuticals

2 Healthcare Stocks That Doubled Investors' Money in 2019

Guardant Health (GH) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.

Guardant Health (GH) Looks Good: Stock Adds 6% in Session

Exact Sciences

Easier ways to look for solid tumors are closer than you think.

Who's Winning the Race for This $100 Billion Healthcare Market?

Teladoc

They're leaders in their markets. And those markets should grow tremendously.

Healthcare Stocks I'd Buy Right Now

Carvana

Roku, Guardant Health, and Carvana have all soared to start the year. Should the buyer beware or let the good times roll?

3 Stocks That Have Doubled in 2019 -- Are They Still Buys?

A new study is planned that could someday reshape colon cancer screenings.

Guardant Health Takes Aim at Exact Sciences

Buckeye Partners

Chico's FAS

Earnings and acquisition activity helped make these stocks stand out.

Why Buckeye Partners, Guardant Health, and Chico's FAS Jumped Today

Traders bid up the stock in response to another strong earnings report.

Why Guardant Health Is Soaring Today

Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q1 2019 Results - Earnings Call Transcript

At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

Guardant Health (GH) to Report Q1 Earnings: What's in Store?

In the latest trading session, Guardant Health (GH) closed at $66.12, marking a -1.9% move from the previous day.

Guardant Health (GH) Stock Sinks As Market Gains: What You Should Know

Celgene

CRISPR Therapeutics

Editas Medicine

Genomic Health

Gilead Sciences

Myriad Genetics

Novartis

Invitae

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

Positive comments and favorable industry conditions helped lift several stocks.

Why Guardant Health Jumped Today

News for Guardant Health Inc Stock (GH)